Myeloma Minute: Healthcare Cost Disruptors


| INNOVATION | Dr. Durie's Blog


New Amazon Project to Rethink Health Care Could Defy the Skeptics

Can Amazon, Berkshire Hathaway, and JPMorgan Chase disrupt our costly healthcare system? IMF Chairman Dr. Brian G.M. Durie is hopeful about the prospect. “Like all of us, they don’t want to stand idly by and do nothing — no matter how difficult,” he says.


| ACTION | Fundraiser


| ACTION | Fundraiser


Great Wine + Great Causes
A Journey Into the Five Senses

Brady and Christen Raanes’ (c)3 Wines sources grapes from the best vineyards in the world, with the mission of passing all profits to charitable organizations. Purchase a bottle and profits will benefit the IMF. Cheers!

Accomplished artist Claudia Meyer hosts her solo art show “Sensoria” at the Castelli Art Space at 5440 W. Washington Blvd. in Los Angeles from February 3-11, 2018. A portion of all sales of her works from this event will benefit the IMF.



| EMPOWERMENT | Give Today 


February 4 Is World Cancer Day

Cancer knows no borders. In 2013, the IMF founded the Global Myeloma Action Network to improve the lives of myeloma patients around the world. Support the IMF this World Cancer Day to fight myeloma globally.


| INNOVATION | Latest Research 


Phase II Results of Selinexor Plus Low-Dose Dexamethasone Published

The publication of the phase II results with selinexor plus low-dose dexamethasone is a step forward for this first-in-class oral agent. This combination has an overall response rate of 21% in heavily pretreated patients, also known as quad-refractory (patients previously treated with four drugs) and penta-refractory (patients treated with five drugs, including daratumumab). These results satisfy an “unmet need” category that improve chances of FDA approval. Even though selinexor plus low-dose dex has some side effects, including low blood counts and fatigue, this regimen may become an important addition to available myeloma therapies.



FDA Clears Hydrashift 2/4 Daratumumab Assay for Testing

The FDA approved the use of Hydrashift 2/4 daratumumab assay for evaluating response in multiple myeloma patients treated with Darzalex® (daratumumab). Darzalex, a fully human monoclonal antibody that binds to CD38, may interfere with immunofixation results in MM patients. The Hydrashift 2/4 daratumumab assay mitigates such interference in immunofixation test results.


| #ASKDRDURIE | Dr. Durie's Weekly Web Video Series



BOSTON Trial Fact Sheet

New selinexor STORM Trial: Learn How to Participate

New ARROW Clinical Trials: Learn How to Participate

New ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

Listen to a Replay: Best of ASH 2017 teleconference

February 3, 2018
IMF Regional Community Workshop
Raleigh-Durham, NC

February 9-10, 2018
IMF Patient & Family Seminar
San Francisco, CA

February 25, 2018
Multiple Myeloma Symposium
Kingston, Jamaica

March 10, 2018
IMF Regional Community Workshop
Denver, CO

March 16-17, 2018
IMF Patient & Family Seminar
Boca Raton, FL

April 21, 2018
IMF Regional Community Workshop
Nashville, TN


subscribe_button.png          donate_button_bottom.png
We Thank Our Sponsors:
Amgen, Celgene Corporation, Genentech, Janssen Oncology, and Takeda Oncology
and individuals like you who supported the IMF this year

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.